Ratings by Guggenheim (Etzer Darout)

Date CompanySymbol Type Rating
(Past)
PT
(Past)
Start $
(End $)
% Chg. Details
9/13/2021 Mirum Pharamceuticals MIRM Maintain Buy
(N/A)
 
 
  Details
7/12/2021 Verve Therapeutics VERV New Coverage Buy
(N/A)
46.00
(59.88)
30.17% Details
5/18/2021 Vascular Biogenics Ltd VBLT New Coverage Buy
(N/A)
2.02
(2.33)
15.35% Details
5/18/2021 Onconova Therapeutics ONTX New Coverage Buy
(N/A)
0.62
(5.11)
724.19% Details
3/8/2021 Soleno Therapeutics Inc. SLNO Maintain Buy
(N/A)
 
 
  Details
10/30/2020 DiaMedica Therapeutics Inc. DMAC New Coverage Buy
(N/A)
4.13
(4.18)
1.21% Details
9/22/2020 CytomX Therapeutics CTMX Downgrade Neutral
(Buy)
6.94
(5.23)
-24.64% Details
9/22/2020 Eidos Therapeutics EIDX Downgrade Neutral
(Buy)
47.60
(122.21)
156.74% Details
8/4/2020 Inventiva SA IVA New Coverage Buy
(N/A)
10.24
(13.90)
35.74% Details
6/1/2020 MacroGenics MGNX Upgrade Buy
(Neutral)
19.24
(20.48)
6.44% Details
3/31/2020 MyoKardia MYOK Maintain Buy
(N/A)
 
 
  Details
3/31/2020 CytomX Therapeutics CTMX Maintain Buy
(N/A)
 
 
  Details
3/3/2020 Forty Seven Inc. FTSV Downgrade Neutral
(Buy)
93.91
(95.51)
1.7% Details
2/20/2020 Eidos Therapeutics EIDX New Coverage Buy
(N/A)
51.00
(122.21)
139.63% Details
2/4/2020 Forty Seven Inc. FTSV Maintain Buy
(N/A)
 
 
  Details
1/27/2020 MyoKardia MYOK Maintain Buy
(N/A)
 
 
  Details
1/6/2020 CytomX Therapeutics CTMX Maintain Buy
(N/A)
 
 
  Details
11/20/2019 MacroGenics MGNX New Coverage Neutral
(N/A)
8.67
(20.48)
136.22% Details
11/20/2019 CytomX Therapeutics CTMX New Coverage Buy
(N/A)
5.17
(5.23)
1.16% Details
9/20/2019 Zealand Pharma A/S ZEAL New Coverage Buy
(N/A)
24.88
(31.95)
28.42% Details
9/20/2019 MyoKardia MYOK New Coverage Buy
(N/A)
55.63
(224.91)
304.3% Details